This website contains information about
INBRIJA® (levodopa inhalation powder)
M-INB-UK-0047
Date of preparation: December 2025
About INBRIJA®
Introducing INBRIJA® – levodopa inhalation powder on demand1
Rapid
Observed relief in as
little as 10 minutes2,3
RELIABLE
Pulmonary route avoids
variability caused by GI
tract absorption4
ON-DEMAND
Supporting patients when
needed, up to 5 times per day4
INBRIJA® - rapid, reliable relief in 10 minutes2,3
Post dose, INBRIJA® delivered:
Rapid onset
of action
observed in
as few as
10 minutes2,3
of action
observed in
as few as
10 minutes2,3
Significant
improvement in
motor function
(p=0.009) (primary
endpoint)2*
improvement in
motor function
(p=0.009) (primary
endpoint)2*
Sustained effect2
*The least squares mean difference between the 84 mg dose and placebo was –3.92 (–6.84 to –1.00) as measured by UPDRS motor score from pre dose to 30 minutes post dose.
In a 12-week, randomised, double-blind, placebo-controlled phase III trial of INBRIJA®, adults with Parkinson’s disease experiencing at least 2 hours of daily OFF time despite stable oral levodopa therapy were enrolled. Participants were randomised (1:1:1) to INBRIJA® 60 mg, 84† mg, or placebo, administered as needed for OFF episodes (up to five times daily) in addition to their standard regimen. The primary endpoint was the change in Unified Parkinson’s disease rating scale (UPDRS) Part III motor score from pre-dose to 30 minutes post-dose at week 12 during an in-clinic OFF period.2
GI; Gastrointestinal; UPDRS, Unified Parkinson’s Disease Rating Scale.
†The recommended dose of INBRIJA® is 2 hard capsules each containing 42 mg levodopa. Each delivered dose per capsule contains 33 mg levodopa.
References:
- 1. INBRIJA® Summary of Product Characteristics.
- 2. LeWitt PA, Hauser RA, Pahwa R, et al; SPAN-PD Study Investigators. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18:145-154.
3. Isaacson SH, Pagan FL, Lew MF, Pahwa R. Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier? Clin Park Relat Disord. 2022;7:100161.- 4. Safirstein BE, Ellenbogen A, Zhao P, Henney HR 3rd, Kegler-Ebo DM, Oh C. Pharmacokinetics of inhaled levodopa administered with oral carbidopa in the fed state in patients with Parkinson’s disease. Clin Ther. 2020;42:1034-1046.